Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon’s consulting and management organization with clinical expertise in the development of cardiovascular products and trials.
“Strong interest in MYDICAR® from investigators and patients emphasizes the substantial unmet medical need in these very sick patients with few other viable options. Patients will be observed for 6 months, and we expect Interim data results to be available mid-2010,” said Krisztina M. Zsebo, Ph.D., president and chief executive officer. “We remain encouraged by the meaningful improvements in cardiac function and overall condition of patients; findings that we believe demonstrate the return toward normal intracellular calcium cycling and contractility in some of the heart muscle cells.”
“The CUPID trial is designed to rescue a failing heart by replacing an enzyme known to play a critical role in healthy cardiac function,” said Mariell Jessup, M.D., Lead Investigator, who works at the University of Pennsylvania. “The objective of the study is not only to improve the symptoms of heart failure but to reverse the severity of the disease in individual patients. The extraordinary team of clinical investigators, Celladon and Momentum Research have made this challenging concept a reality.”